Our long term bearish call on $MFE has proven correct. Our average short price is $43.92. The earning report validates our thesis that the bulk of revenues are coming from what has now been commoditized. The earnings report is in line with what we expected , but a disaster compared
We are exiting $BCRX and $AVAV; please see separate posts for the reasons. We are short on $ACOR with average price of $30.28. Our thesis has not changed in that Ampyra is not a very good drug, although Wall Street has termed it a blockbuster drug. . In the short
$MFE shares are up strongly today on reports that it will unveil a new version of its flagship product on July 7. This run up is offering a good opportunity to build short position. We added to our short position at $42.40 and will add more going into July 7
Right here at $39.87 and continue to short MFE as stock moves higher. MSFT announced in November 2008 that it intended to offer a free anti-virus service. Lately, market participants have forgotten about the threat to MFE’s business and the stock has moved up. This provides a great opportunity to